- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05104099
Evaluation of New Diagnostic Tool Using Fluorescence to Detect High-grade Vulvar Intraepithelial Neoplasia (PhotodiVIN)
Evaluation of the Ability of PpIX Fluorescence to Mark High-grade Vulvar Intraepithelial Neoplasia Following the Methyl Aminolevulinate (Metvixia®) Application
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Priscillia TOSTI
- Phone Number: 00 33 383 598 657
- Email: p.tosti@nancy.unicancer.fr
Study Contact Backup
- Name: Naoual Boujedaini, PhD
- Phone Number: 00 33 383 598 668
- Email: n.boujedaini@nancy.unicancer.fr
Study Locations
-
-
-
Vandœuvre-lès-Nancy, France, 54506
- Recruiting
- Institut de Cancérologie de Lorraine
-
Contact:
- BOUJEDAINI Naoual, PhD
- Phone Number: +33 (0)3 83 59 86 68
- Email: n.boujedaini@nancy.unicancer.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient aged 18 and over,
- With isolated high-grade vulvar intraepithelial neoplasia OR associated with invasive cancer proven histologically by biopsy
- Naive of any vulvovaginal treatment (surgery or radiotherapy)
- No metastases
- WHO <or equal to 3
- Contraception method for women of childbearing potential
- Patient affiliated to the social security scheme
- Patient who understood, signed and dated the information note and the
- consent form,
- Patient able and willing to follow all study procedures in accordance with the protocol.
Exclusion Criteria:
- History of hypersensitivity to the active substance methyl aminolevulinate or to any of the components of the drug (including peanut oil and refined almond oil), soybean or peanut
- Ulceration or hyperpigmented lesions of the vulva
- Patient with porphyria
- Any previous vulvovaginal treatment (surgery or radiotherapy)
- Metastatic disease
- Patient undergoing treatment for any other invasive cancer
- Pregnant, likely to be or breastfeeding patient
- Patient deprived of liberty or under guardianship (including guardianship)
- Inability to undergo medical monitoring of the trial for geographic, social or psychological reasons.
- Patient already included in another therapeutic trial with an experimental molecule,
- Associated pathology that may prevent the patient from receiving METVIXIA application and light exposure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Metvixia application for Photodynamic diagnosis
Patients who benefit Metvixia application to the vulva to realize fluorescence guided biopsies (Photodynamic diagnosis).
|
Metvixia is applied with a spatula, in a thick layer, to clinically visible lesions and all over the vulva. After applying the cream, the area will be covered with a bandage which should remain in place for 3 hours. After 3 hours of application, the bandage and the cream will be carefully removed. The application area will be cleaned and then immediately exposed to a continuous spectrum of light at a wavelength of 405 nm by a xenon lamp. The most fluorescent areas will be identified. Then in white light, the practitioner will perform at least two biopsies under non-topical local anesthesia in the area of application of Metvixia®: one in the fluorescent area and one in the non-fluorescent area. If there is no fluorescent labeling, two samples will be taken from two different non-fluorescent areas. In the event that all the zone is fluorescent , two samples will be taken from two different fluorescent zones. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of the success of the photodynamic diagnosis
Time Frame: 14 days (+/- 4 days) after the photodiagnosis
|
Percentage of patients for whom the procedure successfully demonstrated high-grade vulvar intraepithelial neoplasias in fluorescence confirmed by biopsy. A patient will be considered successful if the presence or absence of fluorescence is consistent with the anatomo-pathological result, that means if her sample in the fluorescent area is positive in pathology and her sample in the non-fluorescent area is negative in anatomo-pathology. For a patient with no fluorescent labeling, the pathological results of her two samples must be negative for the patient to be considered successful. For a patient where the entire area fluoresces, the anatomo-pathological result of her two samples must be positive for the patient to be considered successful. |
14 days (+/- 4 days) after the photodiagnosis
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity of the photodynamic diagnosis
Time Frame: 14 days (+/- 4 days) after the photodiagnosis
|
The sensitivity will correspond to the number of fluorescent zones among the positive zones in anatomopathology.
|
14 days (+/- 4 days) after the photodiagnosis
|
Specifity of the photodynamic diagnosis
Time Frame: 14 days (+/- 4 days) after the photodiagnosis
|
The specificity will correspond to the number of non-fluorescent zones among the negative zones in anatomo-pathology.
|
14 days (+/- 4 days) after the photodiagnosis
|
Intensity of flurescence evaluation
Time Frame: The day of the photo analysis with a specific software
|
The fluorescence intensity will be measured by the signal to noise ratio, also called SNR (Signal to Noise Ratio) on photographie
|
The day of the photo analysis with a specific software
|
Tolerance evaluation
Time Frame: At inclusion, after applying the cream for 3 hours, before and immediately after the blue light exposition and at and the final study visite (14 days +/- 4 after the photodiagnosis)
|
The tolerance of the application will be assessed by the number of grade 3 to 5 toxicity.
The toxicity will be evaluated using the CTCAE v5 scale (Common Terminology for Adverse Events).
The different grade on this scale is 1 to 5 (1 correspond to a asymptomatic or mild symptome, 2 to moderate toxicity, 3 to severe or medically significant but not immediately life-threatening toxicity, 4 to life-threatening consequences or urgent intervention indicated and 5 to the death related to the toxicity.
|
At inclusion, after applying the cream for 3 hours, before and immediately after the blue light exposition and at and the final study visite (14 days +/- 4 after the photodiagnosis)
|
Pain Evaluation
Time Frame: At inclusion, 1 hour after Metvixia application, before and immediately after the blue light exposition and at and the final study visite (14 days +/- 4 after the inclusion)
|
Pain will be assessed using a numerical scale from 0 to 10 (0 corresponds to no pain and 10 to maximum pain)
|
At inclusion, 1 hour after Metvixia application, before and immediately after the blue light exposition and at and the final study visite (14 days +/- 4 after the inclusion)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Lorraine HEJL, MD, Institut de Cancérologie de Lorraine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Uterine Cervical Diseases
- Uterine Diseases
- Precancerous Conditions
- Neoplasms, Squamous Cell
- Uterine Cervical Dysplasia
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Neoplasms
- Carcinoma in Situ
- Carcinoma, Squamous Cell
- Squamous Intraepithelial Lesions of the Cervix
- Photosensitizing Agents
- Dermatologic Agents
- Methyl 5-aminolevulinate
Other Study ID Numbers
- 2021-000568-31
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vulvar Intraepithelial Neoplasia
-
ViMREX GmbHFrankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus...Active, not recruitingVulvar Intraepithelial Neoplasia Grade 2 | Vulvar Intraepithelial Neoplasia Grade 3Germany
-
Medical University of GrazAustrian Science Fund (FWF)CompletedVulvar Intraepithelial NeoplasiaAustria
-
University of Colorado, DenverStryker InstrumentsCompletedVulvar Intraepithelial Neoplasia (VIN)United States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Frantz Viral Therapeutics, LLCActive, not recruitingVulvar Diseases | Vulvar Dysplasia | HPV-Related Vulvar Intraepithelial Neoplasia | Preinvasive Vulvar Disease | Vulva Intraepithelial NeoplasiaUnited States
-
Jun ZhangXiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...RecruitingCervical Cancer | Cervical Intraepithelial Neoplasia | Vaginal Intraepithelial Neoplasia | Vulvar Intraepithelial Neoplasia | Persistent InfectionChina
-
Jun ZhangXiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...RecruitingCervical Cancer | Cervical Intraepithelial Neoplasia | Vaginal Intraepithelial Neoplasia | Vulvar Intraepithelial Neoplasia | Persistent InfectionChina
-
Jun ZhangXiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...Active, not recruitingCervical Cancer | Cervical Intraepithelial Neoplasia | Vaginal Intraepithelial Neoplasia | Vulvar Intraepithelial Neoplasia | Persistent InfectionChina
-
Xiamen Innovax Biotech Co., LtdJiangsu Province Centers for Disease Control and Prevention; Dongtai City Centers...CompletedCervical Cancer | Cervical Intraepithelial Neoplasia | Vaginal Intraepithelial Neoplasia | Vulvar Intraepithelial Neoplasia | Persistent InfectionChina
-
Jun ZhangXiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...CompletedCervical Cancer | Cervical Intraepithelial Neoplasia | Vaginal Intraepithelial Neoplasia | Vulvar Intraepithelial Neoplasia | Persistent InfectionChina
-
Jun ZhangXiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...CompletedA Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent GirlsCervical Cancer | Cervical Intraepithelial Neoplasia | Vaginal Intraepithelial Neoplasia | Vulvar Intraepithelial Neoplasia | Persistent InfectionChina
Clinical Trials on Metvixia Topical Cream
-
Centre Hospitalier Universitaire de NīmesCompleted
-
Amazentis SAproDERM GmbHCompleted
-
Amazentis SAproDERM GmbHCompletedErythema | Skin Inflammation | Sun Damaged SkinGermany
-
Medical University of SilesiaCompletedCannabis | Myofascial Pain | Temporomandibular Disorder | ElectromyographyPoland
-
Memorial Sloan Kettering Cancer CenterIncyte Corporation; Hackensack Meridian HealthCompletedNon-sclerotic Cutaneous Chronic Graft-versus-host DiseaseUnited States
-
Natural Immune Systems IncCompleted
-
Berg, LLCCompletedSuperficial Basal Cell CarcinomaUnited States
-
Pyramid BiosciencesCompletedPsoriasis | Healthy VolunteersUnited States
-
MINO Labs, LLCCompleted
-
Shiraz University of Medical SciencesUnknownHemorrhoidsIran, Islamic Republic of